



## L&G AXA Framlington Health Pn

### Fund objective

The aim of this Fund is to provide long-term capital growth.

### Detailed fund information

**Unit name** L&G AXA Framlington Health Pn

**FE fundinfo Crown Rating** 

**Sector** Specialist

**Domicile** United Kingdom

**Fund currency** GBX

**Unit currency** GBX

**Launch date** 20-Apr-2006

**Fund size** (as at 17-May-2024) £0.3m

**Primary asset class** Equity

**Inc / Acc** Accumulating

### Price and charges

**Bid price** (as at 17-May-2024) GBX 566.10

**Offer price** (as at 17-May-2024) GBX 566.10

**Initial charge** n/a

**Annual charge** 1.23%

### Codes

**Citicode** L168

**ISIN** GB00B0YTDK32

### Management information

**Fund manager** Peter Hughes

**Start date** 14-Jun-2021

**Address** One Coleman Street, London

**Tel** +44 (0) 20 3124 3277 (Main Number)

**Website** www.lgim.com

### Past performance overview fund vs. sector



17/05/2019 - 17/05/2024 Powered by data from FE fundinfo

### Cumulative performance (%)

|                               | YTD  | 3m   | 6m    | 1y   | 3ys   | 5ys   |
|-------------------------------|------|------|-------|------|-------|-------|
| L&G AXA Framlington Health Pn | +9.3 | +3.3 | +13.0 | +9.3 | +31.7 | +70.6 |
| Specialist                    | +4.3 | +3.7 | +8.0  | +9.3 | +6.8  | +19.9 |

### Discrete performance (%)

|                               | YTD  | 2023 | 2022 | 2021  | 2020  | 2019  |
|-------------------------------|------|------|------|-------|-------|-------|
| L&G AXA Framlington Health Pn | +9.3 | +1.6 | +3.0 | +15.5 | +14.5 | +19.4 |
| Specialist                    | +4.3 | +6.5 | -8.7 | +6.9  | +5.4  | +11.6 |

### Growth of £1000 over 3 years

Total return performance of the fund rebased to 1000. Your actual return would be reduced by the cost of buying and selling the fund, and inflation.




■ Fund

20/05/2021 - 17/05/2024 Powered by data from FE fundinfo

All prices in Pence Sterling (GBX) unless otherwise specified. Price performance figures are calculated on a bid price to bid price basis with net income (dividends) reinvested. Performance figures are shown in Sterling.


## Asset allocation

| Key | Rank | Asset class            | % of Fund<br>(28.03.2024) |
|-----|------|------------------------|---------------------------|
| A   | 1    | North America Equities | 67.5                      |
| B   | 2    | Europe Ex UK Equities  | 25.2                      |
| C   | 3    | UK Equities            | 5.2                       |
| D   | 4    | Cash                   | 2.2                       |




## Regional breakdown

| Key | Rank | Region        | % of Fund<br>(28.03.2024) |
|-----|------|---------------|---------------------------|
| A   | 1    | North America | 67.5                      |
| B   | 2    | Europe Ex UK  | 25.2                      |
| C   | 3    | UK            | 5.2                       |
| D   | 4    | Cash          | 2.2                       |



## Sector breakdown

| Key | Rank | Sector                         | % of Fund<br>(28.03.2024) |
|-----|------|--------------------------------|---------------------------|
| A   | 1    | Pharmaceuticals                | 33.6                      |
| B   | 2    | Life Sciences Tools & Services | 29.8                      |
| C   | 3    | Health Care Technology         | 18.9                      |
| D   | 4    | Managed Health Care            | 13.7                      |
| E   | 5    | Cash                           | 2.2                       |
| F   | 6    | Health Care Facilities         | 1.9                       |



## Top ten holdings

| Rank | Holding                      | % of Fund<br>(28.03.2024) |
|------|------------------------------|---------------------------|
| 1    | Eli Lilly & Co               | 9.1                       |
| 2    | Novo Nordisk A               | 7.6                       |
| 3    | UnitedHealth Group Inc       | 7.0                       |
| 4    | Merck & Co Inc               | 5.9                       |
| 5    | Thermo Fisher Scientific Inc | 4.6                       |
| 6    | AstraZeneca PLC              | 3.9                       |
| 7    | Abbott Laboratories          | 3.2                       |
| 8    | Sanofi SA                    | 2.9                       |
| 9    | Boston Scientific Corp       | 2.8                       |
| 10   | McKesson Corp                | 2.8                       |